Ultomiris recommended in EU for children with PNH
26 July 2021 07:00 BST Ultomiris recommended for approval in the EU by CHMP forchildren and adolescents with paroxysmal nocturnal haemoglobinuria Opinion based on results from Ultomiris Phase III trial that showed an established efficacy and safety profile with reduced treatment burden for children with PNH and their families Alexion's Ultomiris (ravulizumab) has been recommended for marketing authorisation in the European Union (EU) for expanded use to include children and adolescents with paroxysmal nocturnal haemoglobinuria (PNH). The Committee for Medicinal Products